Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
REZILIENT4
2025-521775-31-00Phase 3Authorised
- Sponsor
- Taiho Oncology
- Start
- Oct 2025
- Modality
- Small Molecules
- Countries
- 21
01
Overview
Phase 3, randomised, double-blind trial in EGFR-mutated non-small cell lung cancer comparing Zipalertinib + platinum-pemetrexed chemotherapy with Placebo + platinum-pemetrexed chemotherapy (2 arms). Primary endpoint: Disease-free survival by investigator assessment. Planned start Oct 2025; status: authorised.
02
Drugs
zipalertinib
03
Conditions
EGFR-mutated non-small cell lung cancer
Beyond the preview
Go deeper on 2025-521775-31-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521775-31-00.